|
WO2010107847A1
|
|
Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
|
|
CA2738248A1
|
|
Methods and compositions for clostridium difficile toxin production
|
|
CN102089003A
|
|
Recombinant rhinovirus vectors
|
|
UA103316C2
|
|
Replication-defective flavivirus vaccines and vaccine vectors
|
|
NZ602611A
|
|
Replication-defective flavivirus vaccines and vaccine vectors
|
|
US2011110973A1
|
|
Influenza B Vaccines
|
|
MX2010002815A
|
|
Pharmaceutical compositions containing clostridium difficile toxoids a and b.
|
|
CA2676719A1
|
|
Viral vectors and methods of use
|
|
CA2676775A1
|
|
Flavivirus vaccine vector against influenza virus
|
|
CA2676689A1
|
|
Recombinant bicistronic flavivirus vectors
|
|
AU2007318206A1
|
|
Novel neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications
|
|
CA2664791A1
|
|
Recombinant rhinovirus vectors
|
|
ZA200900483B
|
|
Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
|
|
BRPI0714721A2
|
|
construction of recombinant virus vaccines by direct transponder-mediated insertion of foreign immunological determinants into vector virus proteins
|
|
US2009169512A1
|
|
Vaccinia virus strains
|
|
EP1572234A2
|
|
STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
|
|
EP1575979A2
|
|
West nile virus vaccine
|
|
EP2295023A1
|
|
Flavivirus vaccines
|
|
EP2305303A2
|
|
Immunization against Clostridium difficile disease
|
